GW Pharmaceuticals initiates Phase 3 study of Epidiolex for TSC disorder

GW Pharmaceuticals has started a Phase 3 clinical trial of Epidiolex as an adjunctive therapy for treatment of seizures related to tuberous sclerosis complex (TSC), a rare genetic disorder where the most common symptom is epilepsy.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news